- 1 (844) 249-9385 (U.S.)
- 1 (270) 823-1533 (international)
- Conference ID: 13324077
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Serious questions about the XBiotech colon cancer drug were raised after the Xylonix presentation at an ESMO cancer meeting on July 2.
If the messy, confused clinical data disclosed Saturday by XBiotech are any indication, an approval in Europe for its colon cancer drug is far from a sure thing.